WEBULL
WebtradeDownload

Jinhai Medical Technology (SEHK:2225) Looks Fully Priced After Half Year Sales And Loss Improvement

Simply Wall St · 17h ago

Why Jinhai Medical Technology’s Latest Half Year Results Matter

Jinhai Medical Technology (SEHK:2225) has drawn fresh attention after reporting half year 2026 results. Sales reached SGD 34.02 million while the company reported a reduced net loss of SGD 4.36 million.

For investors watching the stock in early September 2026, the combination of higher reported sales and a smaller loss compared with the prior year raises questions about how the business mix and cost base are evolving.

Jinhai Medical Technology’s half year report arrived alongside sharp share price swings, with the stock up 14.05% on the day of the latest HK$4.79 close yet down 6.26% over the past week. Even so, a 40.06% 3 month share price return and a very large 1 year total shareholder return suggest momentum has been building over a longer stretch, as investors react to the improved sales and reduced losses reported in late August 2026.

Spot opportunities with a similar mix of growth ambitions and operational pressure by scanning our hand picked list of 616 high quality undiscovered gems around the market.

The sharp one-day jump in Jinhai Medical Technology after months of strong gains could reflect investors reassessing the smaller loss and higher sales, or it may mostly be sentiment. How does that compare with the current valuation?

Preferred Price-to-Book Multiple of 78.9x: Is It Justified?

Jinhai Medical Technology currently trades on a P/B ratio of 78.9x, compared with an industry level that is much lower. At a last close of HK$4.79, that pricing signals a very rich valuation against typical Professional Services peers.

The P/B ratio compares the company’s market value to its book value, which is the net asset value on the balance sheet. For businesses like Jinhai Medical Technology that are still reporting losses, investors sometimes look at P/B when earnings based measures are less meaningful.

In this case, the valuation is expensive when set against both the Asian Professional Services industry average P/B of 2.1x and a peer average P/B of 0.9x. That wide gap indicates the market is assigning Jinhai Medical Technology a far higher valuation relative to its net assets than comparable companies.

Given those comparisons, anyone watching the stock may want to consider what is being priced in at this level and whether the current share price already reflects a lot of optimism about future progress.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 78.9x (OVERVALUED)

However, Jinhai Medical Technology still reports losses and runs a complex mix of medical and construction related businesses, so any operational setback could quickly challenge this rich valuation.

Find out about the key risks to this Jinhai Medical Technology narrative.

Next Steps

If the tone around Jinhai Medical Technology so far feels cautious, that is by design. It is worth testing that against the numbers yourself. Take a moment to review the key data, weigh the valuation against the risks, and see whether the stock fits your approach by checking the 2 important warning signs.

Looking for more investment ideas beyond Jinhai Medical Technology?

If Jinhai Medical Technology has sharpened your focus today, do not stop here. Broaden your watchlist with a few targeted ideas that match your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.